CO5190684A1 - Uso de antagonistas del factor de liberador de corticotropi- na (corticoliberina o crf) y composiciones relacionadas - Google Patents
Uso de antagonistas del factor de liberador de corticotropi- na (corticoliberina o crf) y composiciones relacionadasInfo
- Publication number
- CO5190684A1 CO5190684A1 CO00060137A CO00060137A CO5190684A1 CO 5190684 A1 CO5190684 A1 CO 5190684A1 CO 00060137 A CO00060137 A CO 00060137A CO 00060137 A CO00060137 A CO 00060137A CO 5190684 A1 CO5190684 A1 CO 5190684A1
- Authority
- CO
- Colombia
- Prior art keywords
- crf
- corticoliberine
- antigonists
- related compositions
- release factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un antagonista de la corticoliberina (CRF) es administrado para tratar una condición seleccionada a partir del grupo que consiste de:a) trastornos que pueden ser tratados mediante la alteración del ritmo circadiano; yb) depresión, adicionalmente en donde un segundo compuesto para el tratamiento de la depresión es administrado, dicho segundo compuesto para tratar la depresión tiene un tiempo de acción el cual es retardado con respecto al de dicho antagonista de la corticoliberina.<EMI FILE="00060137_1" ID="1" IMF=JPEG >
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15118399P | 1999-08-27 | 1999-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5190684A1 true CO5190684A1 (es) | 2002-08-29 |
Family
ID=22537665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00060137A CO5190684A1 (es) | 1999-08-27 | 2000-08-11 | Uso de antagonistas del factor de liberador de corticotropi- na (corticoliberina o crf) y composiciones relacionadas |
Country Status (12)
Country | Link |
---|---|
US (3) | US6432989B1 (es) |
EP (1) | EP1082960A3 (es) |
JP (1) | JP2001097889A (es) |
KR (1) | KR20010050223A (es) |
AU (1) | AU776077B2 (es) |
CA (1) | CA2316662A1 (es) |
CO (1) | CO5190684A1 (es) |
HU (1) | HUP0003386A3 (es) |
IL (1) | IL137935A0 (es) |
NZ (1) | NZ506562A (es) |
PE (1) | PE20010528A1 (es) |
ZA (1) | ZA200004362B (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432989B1 (en) * | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
EP1218023B8 (en) | 1999-10-01 | 2006-05-03 | Johnson & Johnson Consumer Companies, Inc. | Method for calming human beings using personal care compositions |
EP1149583A3 (en) * | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
EP1383747B1 (en) * | 2001-04-30 | 2008-02-20 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
GB2384563A (en) | 2002-01-29 | 2003-07-30 | Johnson & Johnson Consumer | Method of measuring the stress or relaxation level of a mammal |
GB0203045D0 (en) * | 2002-02-08 | 2002-03-27 | Johnson & Johnson Consumer | Method of afefecting sleep and sleep-related behaviours |
JP2005531599A (ja) | 2002-05-29 | 2005-10-20 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾ[4,5−c]ピリジン−4−アミンのための方法 |
US20100189797A1 (en) | 2002-06-10 | 2010-07-29 | Julien Mendlewicz | Oral antidepressant formulation |
WO2003103643A1 (en) | 2002-06-10 | 2003-12-18 | Philippe Kriwin | Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor |
BRPI0409986A (pt) * | 2003-05-05 | 2006-05-09 | Hoffmann La Roche | derivados de pirimidina fundida com atividade de crf |
CA2535249A1 (en) | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
EP1656354B1 (en) | 2003-08-12 | 2007-09-26 | F.Hoffmann-La Roche Ag | Tetrahydroquinazoline derivatives as cfr antagonists |
EP1653914A4 (en) | 2003-08-12 | 2008-10-29 | 3M Innovative Properties Co | COMPOUNDS CONTAINING OXIME SUBSTITUTED IMIDAZO STRUCTURE |
NZ545412A (en) | 2003-08-27 | 2008-12-24 | Coley Pharm Group Inc | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
BRPI0414856A (pt) | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | imidazoquinolinas alcóxi-substituìdas |
EA011926B1 (ru) * | 2003-10-29 | 2009-06-30 | Филипп Кривен | Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия |
CA2545825A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
CN1906193A (zh) | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | 肟取代的咪唑环化合物 |
WO2005051325A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol compositions methods of treatment and delivery |
US8734850B2 (en) * | 2003-11-25 | 2014-05-27 | Flamel Technologies | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form |
MXPA06005910A (es) | 2003-11-25 | 2006-08-23 | 3M Innovative Properties Co | Sistemas de anillo imidazo sustituido y metodos. |
RS50823B (sr) * | 2003-12-11 | 2010-08-31 | Aventis Pharmaceuticals Inc. | Supstituisani 1h-pirolo[3,2-b, 3,2-c, i 2,3-c]piridin-2-karboksamidi i srodni analozi kao inhibitori kazein kinaze i epsilon |
EP1697369A1 (en) * | 2003-12-22 | 2006-09-06 | SB Pharmco Puerto Rico Inc | Crf receptor antagonists and methods relating thereto |
WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
JP2007517044A (ja) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド |
US20050171095A1 (en) * | 2004-01-06 | 2005-08-04 | Pfizer Inc | Combination of CRF antagonists and 5-HT1B receptor antagonists |
WO2005079868A2 (en) * | 2004-02-13 | 2005-09-01 | Sb Pharmco Puerto Rico Inc | Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses |
JP2007522200A (ja) * | 2004-02-13 | 2007-08-09 | ファイザー・プロダクツ・インク | 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ |
AU2005228150A1 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
JP5313502B2 (ja) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | 置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
EP1831226B1 (en) | 2004-12-30 | 2012-08-08 | 3M Innovative Properties Company | Chiral tetracyclic compounds inducing interferon biosynthesis |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
JP2008538550A (ja) | 2005-04-01 | 2008-10-30 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての1−置換ピラゾロ(3,4−c)環状化合物 |
WO2006135733A2 (en) * | 2005-06-10 | 2006-12-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Modulation of peripheral clocks in adipose tissue |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
US8987232B2 (en) * | 2008-09-04 | 2015-03-24 | The University Of Tokyo | Agent for ameliorating brain hypofunction |
WO2011101644A1 (en) | 2010-02-18 | 2011-08-25 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Triazolo [4, 5 - b] pyridin derivatives |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US20180185375A1 (en) * | 2015-06-22 | 2018-07-05 | Embera Neurotherapeutics, Inc. | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
CN110582278B (zh) | 2017-03-10 | 2023-04-18 | 伊姆贝拉神经疗法公司 | 药物组合物及其用途 |
CN109528670B (zh) * | 2018-12-28 | 2021-05-07 | 正大制药(青岛)有限公司 | 一种琥珀酸夫罗曲坦片及其制备方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
ATE177101T1 (de) | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
CN1142817A (zh) | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
US5968944A (en) | 1994-06-06 | 1999-10-19 | Pfizer Inc. | Substituted pyrazoles as corticotropin-releasing factor (CRF) antagonists |
TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
US5646152A (en) * | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
EP0765327B1 (en) | 1994-06-16 | 1999-07-21 | Pfizer Inc. | Pyrazolo and pyrrolopyridines |
ATE182148T1 (de) | 1995-05-12 | 1999-07-15 | Neurogen Corp | Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden |
US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
FR2735777B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US5955613A (en) | 1995-10-13 | 1999-09-21 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
DE69619125T2 (de) | 1995-10-17 | 2002-09-26 | Janssen Pharmaceutica N.V., Beerse | Amino substituierte pyrimidinen und triazinen |
DK0778277T3 (da) | 1995-12-08 | 2003-10-27 | Pfizer | Substituerede heterocycliske derivater som CRF antagonister |
BR9707391A (pt) | 1996-02-07 | 1999-07-20 | Janssen Pharmaceutica Nv | Pirazolpirimidinas como antagonistas de receptor de crf |
PT882051E (pt) | 1996-02-07 | 2002-04-29 | Janssen Pharmaceutica Nv | Tiofenopirimidinas |
NZ331647A (en) | 1996-03-26 | 2000-03-27 | Du Pont Pharm Co | Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives |
US6326368B1 (en) | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
DK0915880T3 (da) | 1996-07-24 | 2008-02-11 | Bristol Myers Squibb Pharma Co | Azolotriaziner og pyrimidiner |
DK0920429T3 (da) | 1996-08-06 | 2003-05-12 | Pfizer | Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater |
US5861398A (en) | 1996-08-26 | 1999-01-19 | Alanex Corporation | Benzoperimidine-carboxylic acids and derivatives thereof |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
AU735401B2 (en) | 1996-08-28 | 2001-07-05 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
AU4270297A (en) | 1996-09-16 | 1998-04-02 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US5760225A (en) | 1996-11-15 | 1998-06-02 | Neurogen Corporation | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands |
DE69720515T2 (de) | 1996-12-18 | 2004-02-19 | Neurogen Corp., Branford | Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren |
AU7890598A (en) | 1996-12-27 | 1998-07-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrimidine compounds and medicinal use thereof |
US5723608A (en) | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
EP0970082A2 (en) | 1997-02-18 | 2000-01-12 | Neurocrine Biosciences, Inc. | Biazacyclic crf antagonists |
KR20010005568A (ko) | 1997-03-26 | 2001-01-15 | 우에하라 아끼라 | 4-테트라히드로피리딜피리미딘 유도체 |
NZ335822A (en) | 1997-04-22 | 2001-05-25 | Neurocrine Biosciences Inc | Preparation and use of 2-methyl-4-dipropylamino-8(2',4'-dichlorophenyl)-quinoline and 2-methyl-4-(N-propyl-N-cyclopropanemethyl)amino-8(2',4'-dichlorophenyl)-quinoline for treating corticotropin-releasing factor related diseases |
CA2272292A1 (en) | 1997-04-22 | 1998-10-29 | Janssen Pharmaceutica N.V. | Crf antagonistic thiophenopyridines |
TW453999B (en) | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
US6143743A (en) | 1997-07-03 | 2000-11-07 | Dupont Pharmaceuticals Company | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
AU8181098A (en) | 1997-07-03 | 1999-01-25 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
AU9021598A (en) | 1997-08-22 | 1999-03-16 | Du Pont Pharmaceuticals Company | Nitrogen substituted imidazo{4,5-c}pyrazoles as corticotropin relea sing hormone antagonists |
NL1010018C2 (nl) | 1997-09-09 | 1999-03-10 | Duphar Int Res | Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. |
CN1542010A (zh) | 1998-01-28 | 2004-11-03 | �Ű�ҩƷ��˾ | 吡咯并三嗪和嘧啶化合物 |
US6432989B1 (en) * | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
-
2000
- 2000-06-05 US US09/587,007 patent/US6432989B1/en not_active Expired - Fee Related
- 2000-08-11 CO CO00060137A patent/CO5190684A1/es not_active Application Discontinuation
- 2000-08-17 IL IL13793500A patent/IL137935A0/xx unknown
- 2000-08-18 EP EP00307074A patent/EP1082960A3/en not_active Withdrawn
- 2000-08-23 JP JP2000251836A patent/JP2001097889A/ja active Pending
- 2000-08-24 ZA ZA200004362A patent/ZA200004362B/xx unknown
- 2000-08-24 HU HU0003386A patent/HUP0003386A3/hu unknown
- 2000-08-25 AU AU53644/00A patent/AU776077B2/en not_active Ceased
- 2000-08-25 NZ NZ506562A patent/NZ506562A/xx unknown
- 2000-08-25 PE PE2000000877A patent/PE20010528A1/es not_active Application Discontinuation
- 2000-08-25 CA CA002316662A patent/CA2316662A1/en not_active Abandoned
- 2000-08-26 KR KR1020000049907A patent/KR20010050223A/ko not_active Application Discontinuation
-
2002
- 2002-06-04 US US10/161,816 patent/US20020156089A1/en not_active Abandoned
-
2003
- 2003-10-01 US US10/676,201 patent/US20040082597A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUP0003386A3 (en) | 2003-08-28 |
EP1082960A2 (en) | 2001-03-14 |
US20020156089A1 (en) | 2002-10-24 |
PE20010528A1 (es) | 2001-05-10 |
IL137935A0 (en) | 2001-10-31 |
EP1082960A3 (en) | 2002-03-20 |
JP2001097889A (ja) | 2001-04-10 |
NZ506562A (en) | 2002-09-27 |
HU0003386D0 (en) | 2000-08-24 |
AU5364400A (en) | 2001-03-01 |
AU776077B2 (en) | 2004-08-26 |
US6432989B1 (en) | 2002-08-13 |
US20040082597A1 (en) | 2004-04-29 |
ZA200004362B (en) | 2002-02-25 |
KR20010050223A (ko) | 2001-06-15 |
CA2316662A1 (en) | 2001-02-27 |
HUP0003386A2 (hu) | 2001-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5190684A1 (es) | Uso de antagonistas del factor de liberador de corticotropi- na (corticoliberina o crf) y composiciones relacionadas | |
CO5570109A1 (es) | Compuestos de dihidropirimidina heterociclicos | |
CO5271657A1 (es) | Derivados de azaindol | |
BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
EA200600582A1 (ru) | Способы и композиции для лечения вирусного гепатита с | |
EA200300023A1 (ru) | 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ | |
WO2000056303A3 (en) | Treatment of immune diseases | |
BR0313743A (pt) | Benzimidazol quinolinonas e usos destas | |
AR030179A1 (es) | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico | |
BR0110420A (pt) | Agonistas muscarìnicos | |
DE69720745D1 (de) | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten | |
EA200000911A1 (ru) | Новые кристаллические формы антивирусного соединения бензимидазола | |
CO5670356A2 (es) | Programa de dosificaicon para un nuevo agente anticanceroso | |
BR0014166A (pt) | Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual | |
CO5050298A1 (es) | Metodo y composicion para tratar impotencia | |
EA200101089A1 (ru) | Новый способ лечения | |
AR008799A1 (es) | Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento | |
CO5271724A1 (es) | Uso de agonistas de prostaglandinas para tratar la disfuncion erectil o la impotencia | |
BR0111630A (pt) | Espiral para inseto | |
PL352551A1 (en) | C16 unsaturated analoques of prostaglandines selective in respect to fp | |
CO5280195A1 (es) | Combinaciones sinteticas de un antagonista de receptor de nk, y un analalogo estructural de gaba | |
AR046672A1 (es) | Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol | |
CO5150166A1 (es) | (s)-10, 11-dihidro-3[2-(5,6,7,8-tetrahidro-1,8-naftiridin -2-il)-etoxi]-5h-dibenzo [a,d] cicloheptano-10-acido acetico | |
BR0112122A (pt) | Composto de rutênio (ii) , uso de um composto, composição farmacêutica, método para tratar e/ou prevenir o câncer, e, processo para preparar um composto | |
EP1580660A3 (en) | Node matching in a dynamic, decentralized environment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |